Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

2023-509210-10-00 Protocol NL85300.041.23 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 Jul 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol NL85300.041.23

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 24
Countries 1
Sites 1

Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

Key facts

Sponsor
Universitair Medisch Centrum Utrecht
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Jul 2024 → ongoing
Decision date (initial)
2024-02-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Utrecht

Sponsor organisation
Universitair Medisch Centrum Utrecht
Address
Heidelberglaan 100
City
Utrecht
Postcode
3584 CX
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Utrecht
Contact name
Clinical trial management imaging

Public contact point

Organisation
Universitair Medisch Centrum Utrecht
Contact name
Clinical trial management imaging

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 24 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Utrecht
Medical oncology, Heidelberglaan 100, 3584 CX, Utrecht

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-07-26 2024-08-13

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-10 Netherlands Acceptable with conditions
2024-02-28
2024-02-29
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-07-08 Netherlands Acceptable with conditions
2024-02-28
2024-07-08
3 SUBSTANTIAL MODIFICATION SM-1 2025-10-21 Netherlands Acceptable
2025-11-06
2025-11-06